Baseline Dual‐Energy Computed Tomography Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Urate‐Lowering Therapy
Authors' conclusion
In people with erosive gout on urate-lowering therapy, higher baseline DECT monosodium urate crystal volume is associated with lower odds of gout remission after two years of treatment, defined by either the preliminary gout remission criteria or simplified gout remission criteria.
Study context
- Population
- People with erosive gout randomised to a serum urate target of <0.20 mmol/L or <0.30 mmol/L on oral ULT, with baseline dual-energy computed tomography (DECT) of the feet and ankles92 analysed at year 2
- Primary endpoint
- Predictors of gout remission (2016 preliminary gout remission criteria and simplified criteria without patient-reported outcomes)
- Follow-up
- Year 2
Methodological detailsdouble-masked, two-year, multivariable logistic regression
- Double-masked
- Two-year
- Multivariable logistic regression
Primary result
As reported in the abstract
Gout remission at year 2 per 1-cm³ increase in baseline DECT monosodium urate crystal volume (the only significant independent predictor)
2016 preliminary gout remission criteria: OR per 1-cm³ increase
0.65
95% CI 0.46–0.93P = 0.02
Simplified gout remission criteria: OR per 1-cm³ increase
0.57
95% CI 0.41–0.78P < 0.001
Further findings
Proportion fulfilling 2016 preliminary gout remission criteria
- Year 1: 11 of 97 (11%)
- Year 2: 21 of 92 (23%)
Proportion fulfilling simplified gout remission criteria
- Year 1: 26 of 97 (27%)
- Year 2: 40 of 92 (44%)
Original publication
Baseline Dual‐Energy Computed Tomography Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Urate‐Lowering Therapy. Arthritis Care Res (Hoboken). Published 29 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →